Thromboembolism Prophylaxis in Gynecologic Surgery

by | Mar 2, 2019 | Uncategorized | 0 comments

All Premium Themes And WEBSITE Utilities Tools You Ever Need! Greatest 100% Free Bonuses With Any Purchase.

Greatest CYBER MONDAY SALES with Bonuses are offered to following date: Get Started For Free!
Purchase Any Product Today! Premium Bonuses More Than $10,997 Will Be Emailed To You To Keep Even Just For Trying It Out.
Click Here To See Greatest Bonuses

and Try Out Any Today!

Here’s the deal.. if you buy any product(s) Linked from this sitewww.Knowledge-Easy.com including Clickbank products, as long as not Google’s product ads, I am gonna Send ALL to you absolutely FREE!. That’s right, you WILL OWN ALL THE PRODUCTS, for Now, just follow these instructions:

1. Order the product(s) you want by click here and select the Top Product, Top Skill you like on this site ..

2. Automatically send you bonuses or simply send me your receipt to consultingadvantages@yahoo.com Or just Enter name and your email in the form at the Bonus Details.

3. I will validate your purchases. AND Send Themes, ALL 50 Greatests Plus The Ultimate Marketing Weapon & “WEBMASTER’S SURVIVAL KIT” to you include ALL Others are YOURS to keep even you return your purchase. No Questions Asked! High Classic Guaranteed for you! Download All Items At One Place.

That’s it !

*Also Unconditionally, NO RISK WHAT SO EVER with Any Product you buy this website,

60 Days Money Back Guarantee,

IF NOT HAPPY FOR ANY REASON, FUL REFUND, No Questions Asked!

Download Instantly in Hands Top Rated today!

Remember, you really have nothing to lose if the item you purchased is not right for you! Keep All The Bonuses.

Super Premium Bonuses Are Limited Time Only!

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Get Paid To Use Facebook, Twitter and YouTube
Online Social Media Jobs Pay $25 - $50/Hour.
No Experience Required. Work At Home, $316/day!
View 1000s of companies hiring writers now!

Order Now!

MOST POPULAR

*****
Customer Support Chat Job: $25/hr
Chat On Twitter Job - $25/hr
Get Paid to chat with customers on
a business’s Twitter account.

Try Free Now!

Get Paid To Review Apps On Phone
Want to get paid $810 per week online?
Get Paid To Review Perfect Apps Weekly.

Order Now
!
Look For REAL Online Job?
Get Paid To Write Articles $200/day
View 1000s of companies hiring writers now!

Try-Out Free Now!

How To Develop Your Skill For Great Success And Happiness Including Become CPA? | Additional special tips From Admin

Competence Development is definitely the number 1 fundamental and chief aspect of realizing a fact financial success in almost all careers as one observed in a lot of our society together with in Worldwide. Therefore fortuitous to discuss together with you in the right after in relation to whatever successful Expertise Expansion is; the best way or what techniques we work to accomplish dreams and eventually one may perform with what someone is in love with to perform just about every daytime for the purpose and meaningful of a 100 % life. Is it so wonderful if you are confident enough to build quickly and come across victory in precisely what you thought, in-line for, regimented and been effective very hard every last day and certainly you grow to be a CPA, Attorney, an owner of a substantial manufacturer or possibly even a medical professional who may seriously chip in very good aid and values to others, who many, any modern culture and network absolutely adored and respected. I can's think I can support others to be major high quality level who will play a role critical alternatives and pain relief valuations to society and communities currently. How satisfied are you if you come to be one like so with your very own name on the headline? I have got there at SUCCESS and conquer most of the hard locations which is passing the CPA tests to be CPA. What is more, we will also go over what are the downfalls, or some other troubles that is likely to be on the manner and the best way I have in person experienced them and will certainly clearly show you tips on how to address them. | From Admin and Read More at Cont'.

Thromboembolism Prophylaxis in Gynecologic Surgery

No Results

No Results

processing….

Venous thromboembolism (VTE) is a leading cause of disability and death in postoperative hospitalized gynecologic patients. Pulmonary embolism (PE) remains the most common preventable cause of hospital death and is responsible for approximately 150,000-200,000 deaths per year in the United States. [1] In general, VTE occurs in the form of a deep venous thrombosis (DVT) or PE.

Other chronic conditions may result from acute conditions such as postthrombotic syndrome, venous insufficiency, and pulmonary hypertension. This article provides practical background and evidence-based recommendations for clinical practice.

Approximately two million patients in the United States are diagnosed with deep venous thrombosis (DVT) each year. Of these patients, nearly 60,000 die and one third develop pulmonary embolism (PE). [2] Overall, PE has a case-fatality rate of approximately 12%, with lower rates in younger patients and higher rates in patients with cancer. [3, 4] First-time–diagnosed venous thromboembolism (VTE) has an incidence of 1-2 per 1,000 individuals per year. [4, 5] Patients at bedrest are 9 times more likely to develop VTE than the general population. [6] The odds ratio of increased VTE risk in hospitalized and surgical patients is 11.1 and 5.9, respectively. [6]

Without thromboprophylaxis, patients who undergo major gynecologic surgery have a prevalence of DVT in the range of 15%-40%. [7] Asymptomatic DVT is also highly associated with the development of significant PE. [8] Because most PE-associated fatalities occur within 30 minutes of onset, leaving a very narrow window for medical intervention, clinicians must identify those at high risk for VTE and administer effective thromboprophylaxis to minimize the occurrence of this potentially preventable cause of death.

Traditionally, gynecologic surgical patients have been classified preoperatively into 1 of 4 risk categories; low, medium, high, and highest risk. [9] This classification is used to determine the most appropriate thromboprophylaxis regimen for specific patients. Based on the procedure type and duration, age, and presence of additional risk factors, a risk of venous thromboembolism (VTE) is determined.

Table 1. Traditional Risk Classification for Gynecologic Surgery* (Open Table in a new window)

Risk level

Definition

Low

Surgery lasting < 30 minutes in patients < 40 years with no additional risk factors

Moderate

Surgery lasting < 30 minutes in patients with additional risk factors; surgery lasting < 30 minutes in patients aged 40-60 years with no additional risk factors; major surgery in patients < 40 years with no additional risk factors

High

Surgery lasting < 30 minutes in patients >60 years or with additional risk factors; major surgery in patients >40 years or with additional risk factors

Highest

Major surgery in patients >60 years plus prior VTE, cancer, or molecular hypercoagulable state

*Modified from ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol. Aug 2007;110(2 Pt 1):429-40. [PMID: 17666620]. [9]

In May 2012, the American College of Chest Physicians (ACCP), [10, 11] in their published evidence-based clinical practice guidelines, described several methods for stratifying the risk of VTE in nonorthopedic surgical patients. This classification is broken down into the risk percentage among patients who would have no VTE prophylaxis: very low (< 0.5%), low (approximately 1.5%), moderate (approximately 3%), and high risk (approximately 6%).

In addition, two methods are described to develop an overall risk score, the Rogers Score and the Caprini Score (see Tables 2 and 3). [1, 11] These scores can then be used to place patients in an ACCP risk class (see Table 4).

Table 2. Rogers Score for VTE Risk Assessment* (Open Table in a new window)

Risk Factor

Risk Score Points

Operation type

 

Respiratory and hemic

9

Cardiovascular

7

Aneurysm

4

Mouth, palate

4

Stomach, intestines

4

Integument

3

Hernia

2

ASA physical status classification

 

3, 4, or 5

2

2

1

Female sex

1

RVU

 

>17

3

10-17

2

2 points for each condition

2

Disseminated cancer

 

Chemotherapy for malignancy within 30 days of surgery

2

Preoperative serum sodium level >145 mmol/L

2

Transfusion >4 units of packed RBCs in 72 hours before surgery

2

Ventilator-dependent

2

1 point for each condition

 

Wound class (clean/contaminated)

1

Preoperative hematocrit level ≤38%

1

Preoperative bilirubin level >1 mg/dL

1

Dyspnea

1

Albumin level < 3.5 mg/dL

1

Emergency

1

0 points for each condition

 

ASA physical status class 1

0

Work RVU < 10

0

Male sex

0

*Modified from Rogers SO Jr, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg. Jun 2007;204(6):1211-21. [PMID: 17544079].

Abbreviations: ASA, American Society of Anesthesiologists; WVU, Work Relative Value Unit

Table 3: Caprini Risk Assessment Model* (Open Table in a new window)

1 Point

2 Points

3 Points

5 Points

Age 41-60 years

Age 61-74 years

Age ≥75 years

Stroke (1 month)

Minor surgery

Arthroscopic surgery

History of VTE

Elective arthroplasty

BMI >25 kg/m2

Major open surgery (>45 minutes)

Family history of VTE

Hip, pelvis, or leg fracture

Swollen legs

Laparoscopic surgery (>45 minutes)

Factor V Leiden

Acute spinal cord injury (< 1 month)

Varicose veins

Malignancy

Prothrombin 20210A

 

Pregnancy or postpartum

Confined to bed (>72 hours)

Lupus anticoagulant

 

History of unexplained or recurrent spontaneous abortion

Immobilizing plaster cast

Anticardiolipin antibodies

 

Oral contraceptives or hormone replacement use

Central venous access

Elevated serum homocysteine

 

Sepsis (< 1 month)

 

Heparin-induced thrombocytopenia

 

Serious lung disease, including pneumonia (< 1 month)

 

Other congenital or acquired thrombophilia

 

Abnormal pulmonary function

 

 

 

Acute myocardial infarction

 

 

 

Congestive heart failure

 

 

 

History of inflammatory bowel disease

 

 

 

Medical patient at bedrest

 

 

 

*Modified from Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. Feb 2010;251(2):344-50. [PMID: 19779324].

Table 4. VTE Risk Scores and Categories for General Surgical Patients [12] * (Open Table in a new window)

VTE Risk Category

Rogers Score

Caprini Score

Baseline Risk of VTE Without Prophylaxis, %

Very low

< 7

0

< 0.5

Low

7-10

1-2

1.5

Moderate

>10

3-4

3

High

N/A

≥5

6

*Modified from Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. Feb 2012;141(2 Suppl):e195S-226S. [PMID: 22315261].

Multiple inherited risk factors influence coagulability but do not usually result in venous thromboembolism (VTE) in the absence of a contributing medical event, such as pregnancy, surgery, or exogenous hormone ingestion. [13] The most prevalent genetic mutations found in patients with VTE are factor V Leiden mutation and prothrombin gene mutation G20210A. Patients with either of these conditions during pregnancy or major surgery are at an increased risk of perioperative VTE.

Factor V Leiden mutation is the most common inherited thrombophilia, affecting 5% of whites. [14, 15] One in 5 patients diagnosed with VTE and 50% of those with thrombophilia are found to have this mutation. Whites are almost the exclusive carrier of the prothrombin G20210A mutation, and it is found in only 6% of patients with VTE. Factor V Leiden causes activated protein C resistance, while the prothrombin G20210A mutation causes an abnormally elevated prothrombin level, resulting in a 3-fold higher VTE rate. [16] Either mutation can be diagnosed via DNA analysis, while factor V Leiden may also be found via an abnormal activated protein C resistance assay result.

Antithrombin-III (AT-III), protein C, and protein S are uncommon causes of VTE but should be considered in patients who test negative for factor V Leiden and prothrombin mutation but report multiple thrombotic events in their family history. Since AT-III, protein C, and protein S inhibit coagulation, heterozygote carriers have a 10-fold increased risk of VTE, and homozygotes have severe thrombotic events soon after birth. [17] Any of these 3 disorders can be diagnosed via serum assays, but results are unreliable during an acute thrombotic event and during anticoagulation therapy.

Genetic or acquired elevated homocysteine levels have been linked to VTE. Homozygous carriers of the methylenetetrahydrofolate reductase variant 677T have slightly elevated homocysteine levels and a slightly increase risk of thrombosis and arteriosclerosis. [18] Dietary deficiencies of folate, vitamin B6, and vitamin B12 result in acquired hyperhomocysteinemia. [13] It is unknown whether homocysteine itself is a risk factor or simply a marker, and it is unclear whether lowering homocysteine levels would decrease VTE risk. [19]

Antiphospholipid syndrome is an acquired thrombophilia associated with both arterial and venous thrombosis. Fifty percent of patients with systemic lupus erythematosus (SLE) test positive for antiphospholipid antibodies. Testing for lupus includes serum assays for both lupus anticoagulant and anticardiolipin antibodies. Lupus anticoagulant is the more significant test since it reveals b2-glycoprotein-1 antibodies, which correlate highly with thromboembolic complications and morbidity during pregnancy. [20] Clinicians should consider testing in patients with VTE, SLE, recurrent pregnancy loss, early and/or severe preeclampsia, and/or thrombocytopenia. [21]

Graded compression stockings or elastic stockings, intermittent pneumatic compression (IPC) devices, low-dose unfractionated heparin (LDUH), low molecular weight heparin (LMWH), fondaparinux, aspirin, inferior vena cava (IVC) filters, and surveillance with venous compression ultrasonography (VCU) have all been used to prevent venous thromboembolism (VTE). The incidence of VTE in gynecologic oncology patients has been reported to be 1%-6.5%. [22, 23, 24]

In high-risk patients, a combined regimen of medical and mechanical prophylaxis may improve clinical efficacy, although there is limited evidence in gynecologic patients. Extrapolation from the general surgery literature suggests a significant benefit from a combined regimen. [25, 26]

Some investigators question the benefits of routine use of VTE prophylaxis in patients who undergo minimally invasive surgery for gynecologic malignancies. [27] In a study that included 419 women who underwent such surgery (at least a simple/radical total laparoscopic hysterectomy or pelvic lymph node dissection), the rate of VTE was 0.57% within 30 postoperative days in the 352 patients (84%) who did not receive any VTE prophylaxis. Of the 62 women who received VTE prophylaxis, no VTEs occurred in the same postoperative time period. [27]

The American College of Obstetricians and Gynecologists (ACOG) recommends that, until more evidence is accumulated, patients undergoing laparoscopic surgery should be stratified by risk category and should receive prophylaxis similar to that provided to patients undergoing laparotomy. [9] Among members of the Society of Gynecologic Oncology, the preferred method of VTE prevention during laparoscopic surgery for high-risk patients was combination prophylaxis. [28]

In general, optimal prophylaxis for gynecologic surgery considers the risk of VTE and bleeding complications, as well as the wishes of the individual patient. [29]

ACOG grades the quality of evidence in the literature according to the method outlined by the U.S. Preventive Services Task Force, as follows:

I: Evidence obtained from at least one properly designed randomized controlled trial

II-1: Evidence obtained from well-designed controlled trials without randomization

II-2: Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group

II-3: Evidence obtained from multiple time series with or without the intervention; dramatic results in uncontrolled experiments could also be regarded as this type of evidence

III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

Then, based on the highest level of evidence found in the data, recommendations are provided and graded by ACOG according to the following categories:

level A: Recommendations are based on good and consistent scientific evidence

level B: Recommendations are based on limited or inconsistent scientific evidence

level C: Recommendations are based primarily on consensus and expert opinion

For the 2012 ACCP guidelines for the prevention of VTE in nonorthopedic surgical patients, the group used the grades of the Recommendations, Assessment, Development, and Evaluation system to assess the quality of evidence and describe the strength of recommendations (see Table 5). [30, 31, 32]

Table 5. Strength of the Recommendations Grading System [12] * (Open Table in a new window)

Grade of Recommendation

Benefit vs Risk and Burdens

Methodologic Strength of Supporting Evidence

Implications

Strong recommendation, high-quality evidence (1A)

Benefits clearly outweigh risk and burdens or vice versa.

Consistent evidence from randomized controlled trials without important limitations or exceptionally strong evidence from observational studies.

Recommendation can apply to most patients in most circumstances. Further research is very unlikely to change our confidence in the estimate of effect.

 

Strong recommendation, moderate-quality evidence (1B)

Benefits clearly outweigh risk and burdens or vice versa.

Evidence from randomized controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies.

Recommendation can apply to most patients in most circumstances. Higher-quality research may well have an important impact on our confidence in the estimate of effect and may change the estimate.

 

Strong recommendation, low- or very-low-quality evidence (1C)

Benefits clearly outweigh risk and burdens or vice versa.

Evidence for at least one critical outcome from observational studies, case series, or randomized controlled trials, with serious flaws or indirect evidence.

Recommendation can apply to most patients in many circumstances. Higher-quality research is likely to have an important impact on our confidence in the estimate of effect and may well change the estimate.

 

Weak recommendation, high-quality evidence (2A)

Benefits closely balanced with risks and burden.

Consistent evidence from randomized controlled trials without important limitations or exceptionally strong evidence from observational studies.

The best action may differ depending on circumstances or patient or societal values. Further research is very unlikely to change our confidence in the estimate of effect.

 

Weak recommendation, moderate-quality evidence (2B)

Benefits closely balanced with risks and burden.

Evidence from randomized controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies.

Best action may differ depending on circumstances or patient or societal values. Higher-quality research may well have an important impact on our confidence in the estimate of effect and may change the estimate.

 

Weak recommendation, low- or very-low-quality evidence (2C)

Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced.

Evidence for at least one critical outcome from observational studies, case series, or randomized controlled trials, with serious flaws or indirect evidence.

Other alternatives may be equally reasonable. Higher-quality research is likely to have an important impact on our confidence in the estimate of effect and may well change the estimate.

*Modified from Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. Feb 2012;141(2 Suppl):e195S-226S. [PMID: 22315261].

A wide variety of venous thromboembolism (VTE) prophylactic measures have been shown to reduce deep venous thrombosis (DVT) formation. However, the real desire for VTE prophylaxis is to prevent fatal PE in gynecologic surgery patients. Since pulmonary embolism (PE) is relatively rare, most studies in the literature have not been sufficiently powered to show a reduction in mortality as a result of VTE prophylaxis. Without hard data, it still seems reasonable to assume that the prevention of VTE will reduce the incidence of PE in gynecologic surgery patients.

The currently available methods include both mechanical and pharmacologic interventions. Mechanical methods promote circulation and reduce venous stasis. Pharmacologic methods prevent clot formation by effects at different points on the clotting cascade. The individual methods and the evidence for using each are discussed below.

Graduated compression stockings have the advantage of being simple and relatively low cost. Postoperative DVT usually develops within 24 hours after surgery. Graduated compression stockings prevent pooling of blood in the calf veins.

A recent Cochrane review reported a 65% reduction in DVT formation with the use graduated compression stockings when compared to no prophylaxis. [33]

The drawbacks of graduated compression stockings include improper fitting, in which the stockings may act as a tourniquet, causing an increase in venous stasis. Because of this, knee-length stockings are recommended. [9] In addition, the use of graduated compression stockings has been associated with an increased risk of skin complications, including ulcers, blisters, and necrosis. [12]

IPC devices diminish blood stasis by repetitively compressing the calf with a removable pneumatic wrap.

Several meta-analyses have assessed the effectiveness of IPC versus no prophylaxis in perioperative patients. These analyses report that IPC reduced the risk of both asymptomatic and distal DVT by 60%. Proximal DVT risk was diminished by 50%. [34] Many studies to date have too few a number of patients to properly assess IPC effectiveness in PE prevention or mortality.

After major gynecologic surgery, IPC devices reduce DVT formation as effectively as LMWH and low-dose heparin. [23, 24, 35] Adherence to ideal IPC use is often suboptimal, but, when used properly, they may increase systemic fibrinolysis, [36, 37] although this was not confirmed in data from a large series analysis. [38, 39] IPC should be worn continuously on the calf until a perioperative patient is fully ambulatory and ready for hospital discharge. [7] One study of intraoperative use of IPC in gynecologic oncology surgical patients showed a 3-fold reduction in VTE. [40]

One of the most extensively studied thromboprophylaxis methods is low doses (10,000-15,000 units/d) of subcutaneously administered unfractionated heparin. LDUH is not only proven effective in VTE prevention, but it also a low cost to administer.

Many studies show that effective DVT prevention is best achieved when LDUH is administered 2 hours prior to surgery and continued every 8-12 hours postoperatively. [7] Benign gynecologic surgery patients benefit from LDUH administered preoperatively and again at 12-hour intervals postoperatively. [7] Gynecologic oncology surgical patients require a different approach of 5,000 units of heparin 2 hours preoperatively, repeated every 8 hours postoperatively in order to effectively prevent VTE. [41]

A published meta-analysis reported that LDUH was associated with an 18% reduction in the odds of death from any cause, a 47% reduction in the odds of fatal PE, and a 41% reduction in the odds of nonfatal PE, along with a 57% increase in the odds of nonfatal major bleeding. [12] Other studies have not shown an increase of intraoperative blood loss with LDUH use but have noted an increase in postoperative wound hematoma formation. [41, 42] When administering LDUH for more than 4 days, patients should be monitored for heparin-induced thrombocytopenia, which is reported in approximately 6% of patients. [41]

Since original studies dating back to 1985, [43] LMWH has been proven an effective thromboprophylaxis. When compared to LDUH, LMWH has once-daily dosing, a greater bioavailability and longer half-life, and, thus, a more predictable form of pharmacokinetics. [44] Studies show that LMWH and LDUH have similar efficacy rates in VTE prevention. [44] Similar risk reduction to intermittent IPC use was also seen when LMWH was administered preoperative and daily postoperatively. [24] In patients undergoing gynecologic oncology surgery, recent prospective trials showed a 2% incidence of VTE when LMWH prophylaxis was administered preoperatively and postoperatively. [45]

Original reports proposed that LMWH yielded a decreased incidence of perioperative bleeding and wound hematoma formation owing to its lower antithrombin activity and increased levels of antifactor Xa. Although more expensive than LDUH, LMWH is rarely associated with heparin-induced thrombocytopenia; thus, screening is not recommend with extended use. [9] However, a recent meta-analysis has shown that LMWH may actually double the risk of major perioperative bleeding and wound hematoma formation. [12] These findings were confirmed in another recent study by the British National Collaborating Centre for Acute Care, which studied GI, gynecologic, urological, and thoracic surgery. [12]

Major risk factors for VTE usually dictate LMWH therapy duration. Noted risk factors include prior VTE, cancer diagnosis, age older than 60 years, extended surgical time, and bedrest. [45] Forty percent of patients with cancer who develop VTE do so more than 3 weeks postoperatively. [45] Four weeks of LMWH administration postoperatively, versus only 1 week of therapy, reduced VTE risk by 60%, with no increase in bleeding or thrombocytopenia. [46]

The combined use of compression stockings and either LDUH or LMWH has been analyzed in the general surgery literature. A Cochrane review of 19 studies revealed that LDUH in conjunction with graduated compression stockings was 4 times more effective in VTE prevention than LDUH alone. [46] A study of neurosurgical patients also showed a significant VTE reduction with combined LMWH and graduated compression stockings compared with compression stockings alone. [46]

In a cost-benefit analysis of prophylaxis for postoperative VTE in patients with gynecologic malignancies, Japanese investigators suggested a strategy that combined unfractionated heparin three times daily combined with graduated compression stockings and intermittent pneumatic compression; close monitoring of oxygen saturation; and perioperative bilateral circumference measurements of the thighs and calves. [47]

There are no randomized trial data in the gynecology literature to prove the benefits of combining mechanical and pharmacologic therapies in VTE prophylaxis. However, if gynecologic patients fall into high-risk VTE categories (ie, >40 years, cancer diagnosis, prior VTE), a dual prophylactic approach may be warranted to reduce both hypercoagulability and venous stasis. [40] Combined therapy is recommended by the Ninth American College of Chest Physicians Consensus Conference for patients at high risk for VTE. [12] A decision analysis in high-risk gynecologic oncology patients found that combined IPC devices and LMWH use is cost-effective. [25]

The ACOG recommends prophylaxis for women undergoing surgery who have deficiencies of protein C, protein S, or AT-III and for heterozygous carriers of factor V Leiden or prothrombin gene mutation G20210A without a personal history of thrombosis. [9] These patients, by definition, would fall into the “highest risk” category for perioperative VTE.

Based on current ACOG and ACCP evidence-based guidelines, below are recommendations for venous thromboembolism (VTE) prophylaxis in gynecologic surgical patients.

Early ambulation (grade 1B)

IPC (grade 2C) placed before the initiation of surgery and continued until the patient is fully ambulatory

Patients at moderate risk for venous thromboembolism (approximately 3%) (ACOG high risk and level A evidence) but not at high risk for bleeding complications LMWH (grade 2B) or dalteparin 2,500 antifactor-Xa units or enoxaparin 40 mg administered subcutaneously 12 hours before surgery and once a day postoperatively until discharge

LDUH (grade 2B) or unfractionated heparin (5,000 units) administered subcutaneously 2 hours before surgery and every 12 hours after surgery until discharge

IPC (grade 2C) placed before the initiation of surgery and continued until the patient is fully ambulatory

IPC (grade 2C) placed before the initiation of surgery and continued until the patient is fully ambulatory

LMWH (grade 2B) or dalteparin 2,500 antifactor-Xa units or enoxaparin 40 mg administered subcutaneously 12 hours before surgery and once a day postoperatively until dischargeLDUH (grade 2B) or unfractionated heparin (5,000 units) administered subcutaneously 2 hours before surgery and every 12 hours after surgery until discharge

PLUS

IPC (grade 2C) placed before the initiation of surgery and continued until the patient is fully ambulatory

LMWH extended for a duration of 4 weeks (grade 1B)

IPC (grade 2C) placed before the initiation of surgery and continued until the patient is fully ambulatory

Martino MA, Borges E, Williamson E, Siegfried S, Cantor AB, Lancaster J, et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol. 2006 Mar. 107(3):666-71. [Medline].

Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996;93:2212–45.

Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19–25.

Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151: 933–8.

Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657–60.

van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631–5.

Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl): 338S–400S.

Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002;30:771–4.

ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol. 2007 Aug. 110(2 Pt 1):429-40. [Medline].

ACOG Committee Opinion No 610: Chronic Antithrombotic Therapy and Gynecologic Surgery. Obstet Gynecol. 2014 Oct. 124:856-62.

Rogers SO Jr , Kilaru RK , Hosokawa P , Henderson WG , Zinner MJ , Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study . J Am Coll Surg . 2007 ; 204 ( 6 ): 1211 – 1221.

Susan R. Kahn, MD; Wendy Lim, MD; Andrew S. Dunn, MD; Mary Cushman, MD; Francesco Dentali, MD; Elie A. Akl, MD, MPH, PhD; Deborah J. Cook, MD, MSc(Epi); Alex A. Balekian, MD, MSHS; Russell C. Klein, MD; Hoang Le, MD, FCCP; Sam Schulman, MD; M. Hassan Murad, MD, MPH Prevention of VTE in Nonsurgical PatientsPrevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHES…

Oger E, Lacut K, Le Gal G, Couturaud F, Guenet D, Abalain JH, et al. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. EDITH Collaborative Study Group. J Thromb Haemost 2006;4:793–9.

Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyak K, van der Meer J, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15–20.

Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004–8.

Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133–4.

Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005;1–12.

Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254–8.

Lentz SR. Mechanisms of homocysteine-induced athero-thrombosis. J Thromb Haemost 2005;3:1646–54.

de Groot PG, Derksen RH. The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Curr Opin Infect Dis 2005;18:205–10.

Bertolaccini ML, Khamashta MA, Hughes GR. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005;1:40–6.

Clarke-Pearson DL, Dodge RK, Synan I, McClelland RC, Maxwell GL. Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. Obstet Gynecol 2003;101:157–63. (level II-2).

Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168: 1146–53; discussion 1153–4.

Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001;98:989–95.

Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80–5.

Wille-Jorgensen P, Rasmussen MS, Andersen BR, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD001217. DOI: 10.1002/14651858.CD001217.

Bouchard-Fortier G, Geerts WH, Covens A, Vicus D, Kupets R, Gien LT. Is venous thromboprophylaxis necessary in patients undergoing minimally invasive surgery for a gynecologic malignancy?. Gynecol Oncol. 2014 Aug. 134(2):228-32. [Medline].

Worley MJ Jr, Rauh-Hain JA, Sandberg EM, Muto MG. Venous thromboembolism prophylaxis for laparoscopic surgery: a survey of members of the Society of Gynecologic Oncology. Int J Gynecol Cancer. 2013 Jan. 23(1):208-15. [Medline].

ACOG Committee Opinion No. 619: Gynecologic surgery in the obese woman. Obstet Gynecol. 2015 Jan. 125:274-8.

Guyatt GH, Oxman AD, Vist GE; et al. GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ 2008 3367650 924-9266.

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ; GRADE Working Group What is “quality of evidence” and why is it important to clinicians?, BMJ 2008 3367651 995-9987.

Guyatt GH, Oxman AD, Kunz R; et al. GRADE Working Group Going from evidence to recommendations, BMJ 2008 3367652 1049-1051.

Sachdeva A, Dalton M, Amaragiri SV, Lees T; Elastic compression stockings for prevention of deep vein thrombosis, Cochrane Database Syst Rev 20107 CD001484.

Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA; Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients, Ann Intern Med 2007 1464 278-288.

Ginzburg E, Cohn SM, Lopez J, Jackowski J, Brown M, Hameed SM. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. Miami Deep Vein Thrombosis Study Group. Br J Surg 2003;90:1338–44.

Kohro S, Yamakage M, Sato K, Sato JI, Namiki A. Intermittent pneumatic foot compression can activate blood fibrinolysis without changes in blood coagulability and platelet activation. Acta Anaesthesiol Scand 2005; 49:660–4.

Tarnay TJ, Rohr PR, Davidson AG, Stevenson MM, Byars EF, Hopkins GR. Pneumatic calf compression, fibrinolysis, and the prevention of deep venous thrombosis. Surgery 1980;88:489–96.

Killewich LA, Cahan MA, Hanna DJ, Murakami M, Uchida T, Wiley LA, et al. The effect of external pneumatic compression on regional fibrinolysis in a prospective randomized trial. J Vasc Surg 2002;36:953–8.

Cahan MA, Hanna DJ, Wiley LA, Cox DK, Killewich LA. External pneumatic compression and fibrinolysis in abdominal surgery. J Vasc Surg 2000;32:537–43.

Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92–8.

Clarke-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990;75: 684–9.

Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227–40.

Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg 1985;72:786–91.

Holzheimer RG. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH). Eur J Med Res 2004;9:150–70.

Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89–95.

Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. ENOXACAN II Investigators. N Engl J Med 2002;346:975–80.

Morimoto A, Ueda Y, Yokoi T, Tokizawa Y, Yoshino K, Fujita M, et al. Perioperative venous thromboembolism in patients with gynecological malignancies: a lesson from four years of recent clinical experience. Anticancer Res. 2014 Jul. 34(7):3589-95. [Medline].

Bahl V, Hu HM, Henke PK, Wakefi eld TW, Campbell DA Jr , Caprini JA . A validation study of a retrospective venous thromboembolism risk scoring method . Ann Surg . 2010 ;251 ( 2 ): 344 – 350.

Wille-Jorgensen P, Rasmussen MS, Andersen BR, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD001217. DOI: 10.1002/14651858.CD001217.

Risk level

Definition

Low

Surgery lasting < 30 minutes in patients < 40 years with no additional risk factors

Moderate

Surgery lasting < 30 minutes in patients with additional risk factors; surgery lasting < 30 minutes in patients aged 40-60 years with no additional risk factors; major surgery in patients < 40 years with no additional risk factors

High

Surgery lasting < 30 minutes in patients >60 years or with additional risk factors; major surgery in patients >40 years or with additional risk factors

Highest

Major surgery in patients >60 years plus prior VTE, cancer, or molecular hypercoagulable state

*Modified from ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol. Aug 2007;110(2 Pt 1):429-40. [PMID: 17666620]. [9]

Risk Factor

Risk Score Points

Operation type

 

Respiratory and hemic

9

Cardiovascular

7

Aneurysm

4

Mouth, palate

4

Stomach, intestines

4

Integument

3

Hernia

2

ASA physical status classification

 

3, 4, or 5

2

2

1

Female sex

1

RVU

 

>17

3

10-17

2

2 points for each condition

2

Disseminated cancer

 

Chemotherapy for malignancy within 30 days of surgery

2

Preoperative serum sodium level >145 mmol/L

2

Transfusion >4 units of packed RBCs in 72 hours before surgery

2

Ventilator-dependent

2

1 point for each condition

 

Wound class (clean/contaminated)

1

Preoperative hematocrit level ≤38%

1

Preoperative bilirubin level >1 mg/dL

1

Dyspnea

1

Albumin level < 3.5 mg/dL

1

Emergency

1

0 points for each condition

 

ASA physical status class 1

0

Work RVU < 10

0

Male sex

0

*Modified from Rogers SO Jr, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg. Jun 2007;204(6):1211-21. [PMID: 17544079].

Abbreviations: ASA, American Society of Anesthesiologists; WVU, Work Relative Value Unit

1 Point

2 Points

3 Points

5 Points

Age 41-60 years

Age 61-74 years

Age ≥75 years

Stroke (1 month)

Minor surgery

Arthroscopic surgery

History of VTE

Elective arthroplasty

BMI >25 kg/m2

Major open surgery (>45 minutes)

Family history of VTE

Hip, pelvis, or leg fracture

Swollen legs

Laparoscopic surgery (>45 minutes)

Factor V Leiden

Acute spinal cord injury (< 1 month)

Varicose veins

Malignancy

Prothrombin 20210A

 

Pregnancy or postpartum

Confined to bed (>72 hours)

Lupus anticoagulant

 

History of unexplained or recurrent spontaneous abortion

Immobilizing plaster cast

Anticardiolipin antibodies

 

Oral contraceptives or hormone replacement use

Central venous access

Elevated serum homocysteine

 

Sepsis (< 1 month)

 

Heparin-induced thrombocytopenia

 

Serious lung disease, including pneumonia (< 1 month)

 

Other congenital or acquired thrombophilia

 

Abnormal pulmonary function

 

 

 

Acute myocardial infarction

 

 

 

Congestive heart failure

 

 

 

History of inflammatory bowel disease

 

 

 

Medical patient at bedrest

 

 

 

*Modified from Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA Jr, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. Feb 2010;251(2):344-50. [PMID: 19779324].

VTE Risk Category

Rogers Score

Caprini Score

Baseline Risk of VTE Without Prophylaxis, %

Very low

< 7

0

< 0.5

Low

7-10

1-2

1.5

Moderate

>10

3-4

3

High

N/A

≥5

6

*Modified from Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. Feb 2012;141(2 Suppl):e195S-226S. [PMID: 22315261].

Grade of Recommendation

Benefit vs Risk and Burdens

Methodologic Strength of Supporting Evidence

Implications

Strong recommendation, high-quality evidence (1A)

Benefits clearly outweigh risk and burdens or vice versa.

Consistent evidence from randomized controlled trials without important limitations or exceptionally strong evidence from observational studies.

Recommendation can apply to most patients in most circumstances. Further research is very unlikely to change our confidence in the estimate of effect.

 

Strong recommendation, moderate-quality evidence (1B)

Benefits clearly outweigh risk and burdens or vice versa.

Evidence from randomized controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies.

Recommendation can apply to most patients in most circumstances. Higher-quality research may well have an important impact on our confidence in the estimate of effect and may change the estimate.

 

Strong recommendation, low- or very-low-quality evidence (1C)

Benefits clearly outweigh risk and burdens or vice versa.

Evidence for at least one critical outcome from observational studies, case series, or randomized controlled trials, with serious flaws or indirect evidence.

Recommendation can apply to most patients in many circumstances. Higher-quality research is likely to have an important impact on our confidence in the estimate of effect and may well change the estimate.

 

Weak recommendation, high-quality evidence (2A)

Benefits closely balanced with risks and burden.

Consistent evidence from randomized controlled trials without important limitations or exceptionally strong evidence from observational studies.

The best action may differ depending on circumstances or patient or societal values. Further research is very unlikely to change our confidence in the estimate of effect.

 

Weak recommendation, moderate-quality evidence (2B)

Benefits closely balanced with risks and burden.

Evidence from randomized controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise) or very strong evidence from observational studies.

Best action may differ depending on circumstances or patient or societal values. Higher-quality research may well have an important impact on our confidence in the estimate of effect and may change the estimate.

 

Weak recommendation, low- or very-low-quality evidence (2C)

Uncertainty in the estimates of benefits, risks, and burden; benefits, risk, and burden may be closely balanced.

Evidence for at least one critical outcome from observational studies, case series, or randomized controlled trials, with serious flaws or indirect evidence.

Other alternatives may be equally reasonable. Higher-quality research is likely to have an important impact on our confidence in the estimate of effect and may well change the estimate.

*Modified from Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. Feb 2012;141(2 Suppl):e195S-226S. [PMID: 22315261].

Howard A Shaw, MD, MBA Clinical Professor of Obstetrics and Gynecology, Yale University School of Medicine; Chief Medical Officer, Medical City Denton

Howard A Shaw, MD, MBA is a member of the following medical societies: American Association for Physician Leadership, American College of Forensic Examiners Institute, American College of Healthcare Executives, American College of Obstetricians and Gynecologists

Disclosure: Nothing to disclose.

Julia A Shaw, MD, MBA, FACOG Assistant Professor and Residency Program Director, Department of Obstetrics and Gynecology, Yale School of Medicine; Medical Director, Yale-New Haven Hospital Women’s Center

Julia A Shaw, MD, MBA, FACOG is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Association for Physician Leadership, Connecticut State Medical Society, AAGL, North American Menopause Society

Disclosure: Nothing to disclose.

Kris Strohbehn, MD Professor of Obstetrics and Gynecology, Geisel School of Medicine at Dartmouth; Director, Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center

Kris Strohbehn, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American College of Surgeons, American Urogynecologic Society, Society of Gynecologic Surgeons

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: I am on the Board for the Society of Gynecologic Surgeons (SGS). SGS is a non-profit organization whose mission is: “is to promote excellence in gynecologic surgery through acquisition of knowledge and improvement of skills…”.

Thromboembolism Prophylaxis in Gynecologic Surgery

Research & References of Thromboembolism Prophylaxis in Gynecologic Surgery|A&C Accounting And Tax Services
Source

From Admin and Read More here. A note for you if you pursue CPA licence, KEEP PRACTICE with the MANY WONDER HELPS I showed you. Make sure to check your works after solving simulations. If a Cashflow statement or your consolidation statement is balanced, you know you pass right after sitting for the exams. I hope my information are great and helpful. Implement them. They worked for me. Hey.... turn gray hair to black also guys. Do not forget HEALTH? Competency Expansion is definitely the number 1 necessary and chief aspect of accomplishing a fact financial success in just about all jobs as you discovered in your modern culture and even in Worldwide. Consequently fortunate enough to talk about together with you in the next with regards to what precisely flourishing Ability Progression is;. how or what methods we work to acquire ambitions and at some point one might operate with what those enjoys to perform every time of day for a extensive everyday life. Is it so superb if you are confident enough to establish proficiently and acquire achievements in just what exactly you thought, targeted for, self-disciplined and functioned hard every last day and most certainly you turned out to be a CPA, Attorney, an holder of a huge manufacturer or even a healthcare professional who might highly bring about terrific benefit and principles to other people, who many, any world and local community definitely popular and respected. I can's believe I can assist others to be main expert level who seem to will bring about significant answers and relief valuations to society and communities in these days. How thrilled are you if you turned into one similar to so with your personally own name on the label? I get arrived on the scene at SUCCESS and beat all of the really difficult parts which is passing the CPA tests to be CPA. Besides, we will also deal with what are the problems, or other sorts of complications that may just be on the option and the way in which I have privately experienced them and can exhibit you easy methods to conquer them.

Send your purchase information or ask a question here!

11 + 6 =

0 Comments

Submit a Comment

World Top Business Management Tips For You!

Business Best Sellers

 

Get Paid To Use Facebook, Twitter and YouTube
Online Social Media Jobs Pay $25 - $50/Hour.
No Experience Required. Work At Home, $316/day!
View 1000s of companies hiring writers now!
Order Now!

 

MOST POPULAR

*****

Customer Support Chat Job: $25/hr
Chat On Twitter Job - $25/hr
Get Paid to chat with customers on
a business’s Twitter account.
Try Free Now!

 

Get Paid To Review Apps On Phone
Want to get paid $810 per week online?
Get Paid To Review Perfect Apps Weekly.
Order Now!

Look For REAL Online Job?
Get Paid To Write Articles $200/day
View 1000s of companies hiring writers now!
Try-Out Free Now!

 

 

Thromboembolism Prophylaxis in Gynecologic Surgery

error: Content is protected !!